Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
Authors
- Andreas M. Schmitt (ORCID: https://orcid.org/0000-0002-9568-8164)
- Sapna Pradyuman Patel (ORCID: https://orcid.org/0000-0003-1339-1517)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
Institutions
- University Hospital of Basel (CH)
- Royal Marsden Hospital (GB)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1200/jco-24-01572
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.54